Xaliproden (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Xaliproden" in Vietnamese language version.

refsWebsite

Global rank Vietnamese rank

9nih.gov

4^th place

7^th place

6doi.org

2^nd place

3archive.org

6^th place

4^th place

archive.org

Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). “Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex”. British Journal of Pharmacology. 127 (1): 139–44. doi:10.1038/sj.bjp.0702545. PMC 1566010. PMID 10369466.
Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). “Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons”. British Journal of Pharmacology. 128 (7): 1385–92. doi:10.1038/sj.bjp.0702910. PMC 1571767. PMID 10602316.
Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). “Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats”. Invest Radiol. 37 (6): 321–7. doi:10.1097/00004424-200206000-00003. PMID 12021588.

doi.org

Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). “Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex”. British Journal of Pharmacology. 127 (1): 139–44. doi:10.1038/sj.bjp.0702545. PMC 1566010. PMID 10369466.
Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). “Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons”. British Journal of Pharmacology. 128 (7): 1385–92. doi:10.1038/sj.bjp.0702910. PMC 1571767. PMID 10602316.
Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN; Robberecht, W (2004). “Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials”. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 5 (2): 107–17. doi:10.1080/14660820410019602. PMID 15204012.
Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). “Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats”. Invest Radiol. 37 (6): 321–7. doi:10.1097/00004424-200206000-00003. PMID 12021588.
Susman, E (2006). “Xaliproden lessens oxaliplatin-mediated neuropathy”. The Lancet Oncology. 7 (4): 288. doi:10.1016/S1470-2045(06)70639-8. PMID 16598880.
Wolf, S; Barton, D; Kottschade, L; Grothey, A; Loprinzi, C (2008). “Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies”. European Journal of Cancer. 44 (11): 1507–15. doi:10.1016/j.ejca.2008.04.018. PMID 18571399.

nih.gov

pubmed.ncbi.nlm.nih.gov

Appert-Collin, A; Duong, FH; Passilly Degrace, P; Warter, JM; Poindron, P; Gies, JP (2005). “MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden”. International Journal of Immunopathology and Pharmacology. 18 (1): 21–31. PMID 15698508.
Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). “Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex”. British Journal of Pharmacology. 127 (1): 139–44. doi:10.1038/sj.bjp.0702545. PMC 1566010. PMID 10369466.
Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). “Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons”. British Journal of Pharmacology. 128 (7): 1385–92. doi:10.1038/sj.bjp.0702910. PMC 1571767. PMID 10602316.
Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN; Robberecht, W (2004). “Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials”. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 5 (2): 107–17. doi:10.1080/14660820410019602. PMID 15204012.
Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). “Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats”. Invest Radiol. 37 (6): 321–7. doi:10.1097/00004424-200206000-00003. PMID 12021588.
Susman, E (2006). “Xaliproden lessens oxaliplatin-mediated neuropathy”. The Lancet Oncology. 7 (4): 288. doi:10.1016/S1470-2045(06)70639-8. PMID 16598880.
Wolf, S; Barton, D; Kottschade, L; Grothey, A; Loprinzi, C (2008). “Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies”. European Journal of Cancer. 44 (11): 1507–15. doi:10.1016/j.ejca.2008.04.018. PMID 18571399.

ncbi.nlm.nih.gov

Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). “Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex”. British Journal of Pharmacology. 127 (1): 139–44. doi:10.1038/sj.bjp.0702545. PMC 1566010. PMID 10369466.
Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). “Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons”. British Journal of Pharmacology. 128 (7): 1385–92. doi:10.1038/sj.bjp.0702910. PMC 1571767. PMID 10602316.